| Symbol | IKT |
|---|---|
| Name | INHIBIKASE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1000 N. WEST STREET,SUITE 1200, WILMINGTON, Delaware, 19801, United States |
| Telephone | +1 302 295-3800 |
| Fax | — |
| — | |
| Website | https://www.inhibikase.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001750149 |
| Description | Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinsons disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinsons disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062874 <b>Size:</b> 14 KB
Read moreNew Form SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001831942-26-000019 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-226561 <b>Size:</b> 11 KB
Read more(30% Negative) INHIBIKASE THERAPEUTICS, INC. (IKT) Reports Q2 2026 Financial Results
Read moreInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Read moreInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Read moreNew Form ARS - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197321 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197177 <b>Size:</b> 6 MB
Read moreNew Form PRE 14A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-163935 <b>Size:</b> 3 MB
Read more(80% Positive) INHIBIKASE THERAPEUTICS, INC. (IKT) Announces Enrollment Update for Variables Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07365332 | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Phase3 | Pulmonary Arterial Hypertension | Recruiting | 2026-04-23 | 2029-12-01 | ClinicalTrials.gov |
| NCT06643143 | A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) | Phase2 | Pulmonary Arterial Hypertension (PAH) | Withdrawn | 2025-06-30 | 2027-06-30 | ClinicalTrials.gov |
| NCT05623774 | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg | Phase1 | CML | Completed | 2022-12-16 | 2024-12-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | RECRUITING | NCT07365332 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | WITHDRAWN | NCT06643143 |
| IkT-001Pro | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | WITHDRAWN | NCT06643143 |
| IkT-001Pro | Other | Phase PHASE1 | CML | COMPLETED | NCT05623774 |
| Imatinib Mesylate | Other | Phase PHASE1 | CML | COMPLETED | NCT05623774 |
| Placebo | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | NOT_YET_RECRUITING | NCT07365332 |
| IKT-001 | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | NOT_YET_RECRUITING | NCT07365332 |